CA2093513A1 - Methode et compositions visant a freiner le rejet des allogreffes chez les mammiferes - Google Patents

Methode et compositions visant a freiner le rejet des allogreffes chez les mammiferes

Info

Publication number
CA2093513A1
CA2093513A1 CA2093513A CA2093513A CA2093513A1 CA 2093513 A1 CA2093513 A1 CA 2093513A1 CA 2093513 A CA2093513 A CA 2093513A CA 2093513 A CA2093513 A CA 2093513A CA 2093513 A1 CA2093513 A1 CA 2093513A1
Authority
CA
Canada
Prior art keywords
methods
mammals
allograft
compositions
allograft rejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2093513A
Other languages
English (en)
Other versions
CA2093513C (fr
Inventor
Howard L. Weiner
David A. Hafler
Charles B. Carpenter
Mohamed Sayegh
Zhengyi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2093513A1 publication Critical patent/CA2093513A1/fr
Application granted granted Critical
Publication of CA2093513C publication Critical patent/CA2093513C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention décrit des procédés servant à supprimer le rejet d'une allogreffe chez des mammifères comprenant l'administration audit mammifère, ayant subi ou étant sur le point de subir l'implantation chirurgicale d'une allogreffe, d'un agent sélectionné à partir du groupe constitué par le tissu splénique d'un donneur d'allogreffe, d'extraits spléniques, de lymphocytes cultivés à partir d'un donneur d'allogreffe, des extraits desdits lymphocytes cultivés, des antigènes MHC (complexe majeur d'histocompatibilité), des fragments suppressifs de rejet de transplantation et des analogues d'antigènes MHC sous forme orale ou d'aérosol. L'invention décrit également des formulations et des formes de dosage pharmaceutiques s'appliquant auxdits procédés.
CA002093513A 1990-10-31 1991-10-31 Methode et compositions visant a freiner le rejet des allogreffes chez les mammiferes Expired - Fee Related CA2093513C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60782690A 1990-10-31 1990-10-31
US607,826 1990-10-31

Publications (2)

Publication Number Publication Date
CA2093513A1 true CA2093513A1 (fr) 1992-05-01
CA2093513C CA2093513C (fr) 1999-03-23

Family

ID=24433875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002093513A Expired - Fee Related CA2093513C (fr) 1990-10-31 1991-10-31 Methode et compositions visant a freiner le rejet des allogreffes chez les mammiferes

Country Status (11)

Country Link
US (2) US5681556A (fr)
EP (1) EP0555413A4 (fr)
JP (1) JP2547162B2 (fr)
KR (1) KR0161235B1 (fr)
AU (1) AU662500B2 (fr)
BR (1) BR9107055A (fr)
CA (1) CA2093513C (fr)
HU (1) HUT63957A (fr)
IL (1) IL99864A (fr)
NO (1) NO931536D0 (fr)
WO (1) WO1992007581A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
PT503648E (pt) * 1991-03-12 2000-10-31 Biogen Inc Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
GB9319429D0 (en) * 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
WO1995020661A1 (fr) * 1994-01-27 1995-08-03 Bresatec Ltd. Procedes et substances destines a la prise en charge du rejet hyperaigu suite a une heterogreffe chez l'homme
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
JPH08239324A (ja) * 1995-03-03 1996-09-17 Fusanori Hamashima 免疫抑制剤
US20020155117A1 (en) * 1996-04-04 2002-10-24 Nicole Suciu-Foca Method for detecting organ allograft rejection and uses thereof
EP2301567A1 (fr) * 1997-02-28 2011-03-30 Enzo Therapeutics, Inc. Réglulation immunitaire négative sélective (SIDR) pour transplantation
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20020012667A1 (en) * 2000-05-16 2002-01-31 Mcmichael John Method for preventing allograft rejection
DE60129552T2 (de) 2000-05-24 2008-04-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services E-selectin zur behandlung oder vorbeugung von schlaganfall
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
WO2003009740A2 (fr) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
EP1446113A4 (fr) * 2001-10-25 2006-12-06 Atherogenics Inc Composes et methodes de traitement d'un rejet de greffe
EP1750747A1 (fr) 2004-05-07 2007-02-14 Astellas US LLC Polypeptide lfa-3 soluble destine a traiter de troubles viraux

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5899419A (ja) * 1981-12-07 1983-06-13 Green Cross Corp:The 免疫抑制剤
JPS59116224A (ja) * 1982-10-01 1984-07-05 デイミトリ・アダモポ−ロス 免疫反応を抑制する組成物およびその製法
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5011037A (en) * 1989-11-30 1991-04-30 Adolph Coors Company Container end member
RU2054180C1 (ru) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций

Also Published As

Publication number Publication date
JP2547162B2 (ja) 1996-10-23
NO931536L (no) 1993-04-27
BR9107055A (pt) 1993-09-21
AU662500B2 (en) 1995-09-07
CA2093513C (fr) 1999-03-23
IL99864A (en) 2000-11-21
WO1992007581A1 (fr) 1992-05-14
HU9301252D0 (en) 1993-07-28
KR930701969A (ko) 1993-09-08
NO931536D0 (no) 1993-04-27
IL99864A0 (en) 1992-08-18
US5788968A (en) 1998-08-04
AU8942691A (en) 1992-05-26
HUT63957A (en) 1993-11-29
EP0555413A1 (fr) 1993-08-18
US5681556A (en) 1997-10-28
JPH05508663A (ja) 1993-12-02
KR0161235B1 (ko) 1998-12-01
EP0555413A4 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
CA2093513A1 (fr) Methode et compositions visant a freiner le rejet des allogreffes chez les mammiferes
CA2117492A1 (fr) Antigene de voisinage supprimant des maladies immunitaires
IL96734A0 (en) Aerosol formulations of autoantigens
AR059693A2 (es) Una composicion farmaceutica de micofenolato y su uso
AU8050791A (en) Compositions and methods for the controlled release of soluble active substances
EP0573423A4 (en) Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
HK33294A (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
AU8762991A (en) Human papilloma viral protein expression for use in vaccine compositions
EP1764103A3 (fr) Compositions d'amifostine cristalline et leurs procédés de préparation et d'utilisation
AU8096591A (en) Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof
HUT57203A (en) Process for substituted benzimidazol and paharmaceutical composition containing them
HK1011503A1 (en) Immunosuppressive compositions
WO1991015512A3 (fr) Polypeptides d'enveloppe du vih
IL94558A0 (en) Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
IT1224574B (it) Fattore di attivazione di leucociti neutrofili, procedimento di preparazione, nonche' composizioni farmaceutiche che lo contengono
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
AU7125991A (en) Novel antiulcer substance
IL93165A0 (en) Phenylhydrazones,their preparation and pharmaceutical compositions containing them
EP0351876A3 (fr) Composition pour augmenter l'effet de vaccination
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions
EP0963755A3 (fr) Utilisation des benzopyranes pour la prévention de rejets de graiffes
IT1217789B (it) Composizione farmaceutica cue si accumula nella pelle e procedimento per la sua preparazione
EP0326067A3 (fr) Utilisation de cyclophyline comme agent anti-inflammatoire et immunomodulateur
EP0836850A3 (fr) Méthode pour prévenir le rejet d'allogreffes

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed